Repaglinide Tablets

Details for the public consultation of this monograph are as follows:

<table>
<thead>
<tr>
<th>EAG/Panel/Working Party</th>
<th>Medicinal Chemicals 1</th>
</tr>
</thead>
</table>
| Contact Details         | helen.corns@mhra.gov.uk  
                          laxsaan.elanganathan@mhra.gov.uk |
| Deadline for Comment    | 30th September 2019 |
| Target Publication Date (subject to change) | BP 2021 |
| Notes                   | New monograph  
                          If limits are too restrictive, please provide batch/stability data to demonstrate that an increase is required. |

Action and use

Stimulates insulin release; treatment of diabetes mellitus.

**DEFINITION**

Repaglinide Tablets contain Repaglinide.

*The tablets comply with the requirements stated under Tablets and with the following requirements.*

**Content of repaglinide, C_{27}H_{36}N_{2}O_{4}**

95.0 to 105.0% of the stated amount.

**IDENTIFICATION**

A. Carry out the method for *thin-layer chromatography*, *Appendix III A*, using the following solutions prepared in methanol.

1. Mix with the aid of ultrasound a quantity of powdered tablets containing 5 mg of Repaglinide with 15 mL of methanol. Dilute to 50 mL, filter (a 0.45-µm nylon filter is suitable) and use the filtrate.

2. 0.01% w/v of repaglinide BPCRS.

**CHROMATOGRAPHIC CONDITIONS**

(a) Use as the coating *silica gel F_{254}* (Merck silica gel 60 F_{254} plates are suitable).

(b) Use the mobile phase as described below.

(c) Apply 25 µL of each solution.

(d) Develop the plate to 5 cm.

(e) After removal of the plate, dry in air and examine under *ultraviolet light (254 nm)*.
MOBILE PHASE

25 volumes of methanol, 30 volumes of toluene and 45 volumes of dichloromethane.

CONFIRMATION

The principal spot in the chromatogram obtained with solution (1) is similar in position and size to that in the chromatogram obtained with solution (2).

B. In the Assay, the retention time of the principal peak in the chromatogram obtained with solution (1) is similar to that of the peak in the chromatogram obtained with solution (2).

TESTS

Dissolution

Comply with the dissolution test for tablets and capsules, Appendix XII B1.

TEST CONDITIONS

(a) Use Apparatus 2, rotating the paddle at 50 revolutions per minute.
(b) Use 900 mL of 0.1 M hydrochloric acid, at a temperature of 37°, as the medium.

PROCEDURE

(1) After 30 minutes withdraw a sample of the medium and filter (a 0.45-µm Millex LCR PTFE filter is suitable). Use the filtered medium, diluted with the dissolution medium if necessary to produce a solution expected to contain 0.00006% w/v of Repaglinide.
(2) 0.00006% w/v of repaglinide BPCRS in methanol. Dilute 1 volume to 100 volumes with the medium.

CHROMATOGRAPHIC CONDITIONS

(a) Use a stainless steel column 12.5 cm × 4.6 mm packed with end-capped octadecylsilyl silica gel for chromatography (10 µm) (Nucleosil C18 is suitable).
(b) Use isocratic elution and the mobile phase described below.
(c) Use a flow rate of 1 mL per minute.
(d) Use a column temperature of 40°.
(e) Use fluorimetric detection with an excitation wavelength of 244 nm and an emission wavelength of 348 nm.
(f) Inject 20 µL of each solution.

MOBILE PHASE

11 volumes of methanol, 40 volumes of 0.01 M potassium dihydrogen orthophosphate adjusted to pH 2.3 with orthophosphoric acid and 49 volumes of acetonitrile.

SYSTEM SUITABILITY

The test is not valid unless, in the chromatogram obtained with solution (2), the symmetry factor of the peak due to repaglinide is between 0.8 and 1.8.

DETERMINATION OF CONTENT

Calculate the total content of repaglinide, C_{27}H_{36}N_{2}O_{4}, in the medium from the chromatograms obtained and using the declared content of C_{27}H_{36}N_{2}O_{4}, in repaglinide BPCRS.
LIMITS

The amount of repaglinide released is not less than 75% (Q) of the stated amount.

Related substances

Carry out the method for liquid chromatography, Appendix III D, using the following solutions, protected from light and prepared in a mixture of equal volumes of acetonitrile and mobile phase A (solution A).

1. Shake a quantity of the powdered tablets containing 5 mg of Repaglinide in 2 mL of water. Add 10 mL of solution A and mix with the aid of ultrasound. Allow to cool, and dilute to 20 mL. Centrifuge and use the supernatant liquid.
2. Dilute 1 volume of solution (1) to 100 volumes. Further dilute 1 volume to 5 volumes.
3. 0.0001% w/v each of repaglinide BPCRS and repaglinide impurity 1 BPCRS.
4. 0.1% w/v of repaglinide for system suitability EPCRS.

CHROMATOGRAPHIC CONDITIONS

(a) Use a stainless steel column 15 cm × 4.6 mm packed with end-capped extra-dense bonded octylsilyl silica gel for chromatography (5 µm) (Zorbax Eclipse XDB C8 is suitable).
(b) Use gradient elution and the mobile phase described below.
(c) Use a flow rate of 1.5 mL per minute.
(d) Use a column temperature of 40°.
(e) Use detection wavelengths of 210 nm and 240 nm.
(f) Inject 20 µL of each solution.

MOBILE PHASE

Mobile phase A 0.02 M potassium dihydrogen orthophosphate adjusted to pH 2.9 with orthophosphoric acid.

Mobile phase B acetonitrile.

<table>
<thead>
<tr>
<th>Time (Minutes)</th>
<th>Mobile phase A (% v/v)</th>
<th>Mobile phase B (% v/v)</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>0-4</td>
<td>75</td>
<td>25</td>
<td>isocratic</td>
</tr>
<tr>
<td>4-30</td>
<td>75→50</td>
<td>25→50</td>
<td>linear gradient</td>
</tr>
<tr>
<td>30-40</td>
<td>50</td>
<td>50</td>
<td>isocratic</td>
</tr>
<tr>
<td>40-41</td>
<td>50→75</td>
<td>50→25</td>
<td>linear gradient</td>
</tr>
<tr>
<td>41-50</td>
<td>75</td>
<td>25</td>
<td>re-equilibration</td>
</tr>
</tbody>
</table>

When the chromatograms are recorded under the prescribed conditions, the relative retentions with reference to repaglinide (retention time about 24 minutes) are: impurity A, about 0.1; impurity B, about 0.4; impurity C, about 0.6; impurity 1, about 1.05; and impurity D, about 1.6.

SYSTEM SUITABILITY

The test is not valid unless, in the chromatogram obtained with solution (3):

At 210 nm

the signal to noise ratio of the principal peak in the chromatogram obtained with solution (2) is at least 40;
At 240 nm

the resolution between repaglinide and impurity 1 is at least 1.8.

LIMITS

At 210 nm

Identify any peak corresponding to impurity C in the chromatogram obtained with solution (1), using the chromatogram obtained with solution (4), and multiply the area of this peak by a correction factor of 2.2.

In the chromatogram obtained with solution (1):

the area of any peak corresponding to impurity C is not greater than 2.5 times the area of the peak in the chromatogram obtained with solution (2) (0.5%).

At 240 nm

Identify any peak corresponding to impurities A and B in the chromatogram obtained with solution (1), using the chromatogram obtained with solution (4), and multiply the areas of these peak by a correction factor of 0.6 and 0.7 respectively.

In the chromatogram obtained with solution (1):

the area of any peak corresponding to impurity A is not greater than 2.5 times the area of the peak in the chromatogram obtained with solution (2) (0.5%);

the area of any other secondary peak is not greater than the area of the principal peak in the chromatogram obtained with solution (2) (0.2%).

Disregard any peak with an area less than half the area of the principal peak in the chromatogram obtained with solution (2) (0.1%).

The sum of all impurities is not greater than 1.0%.

Uniformity of content

Repaglinide Tablets containing less than 2 mg and/or less than 2% w/w of Repaglinide comply with the requirements stated under Tablets using the following method of analysis. Carry out the method for liquid chromatography, Appendix III D, using the following solutions.

1. Mix with the aid of ultrasound one tablet with 3 mL of mobile phase and shake for 15 minutes, dilute to 5 mL with mobile phase and filter (a 0.45-µm Millex LCR PTFE filter is suitable). Dilute the filtrate, if necessary, with mobile phase to produce a solution containing the equivalent of 0.01% w/v of repaglinide.
2. 0.1% w/v of repaglinide BPCRS in methanol. Dilute 1 volume to 10 volumes with the mobile phase.
3. 0.001% w/v each of repaglinide BPCRS and repaglinide impurity 1 BPCRS in methanol. Dilute 1 volume to 10 volumes with the mobile phase.

CHROMATOGRAPHIC CONDITIONS

a) Use a stainless steel column 15 cm × 4.6 mm packed with end-capped extra-dense bonded octylsilyl silica gel for chromatography (5 µm) (Zorbax Eclipse XDB C8 is suitable).

b) Use isocratic elution and the mobile phase described below.
(c) Use a flow rate of 1 mL per minute.
(d) Use a column temperature of 45°.
(e) Use a detection wavelength of 242 nm.
(f) Inject 10 µL of each solution.

MOBILE PHASE

25 volumes of 0.007 M potassium dihydrogen orthophosphate adjusted to pH 2.5 with orthophosphoric acid and 75 volumes of methanol.

When the chromatograms are recorded under the prescribed conditions, the retention time of repaglinide is about 6 minutes.

SYSTEM SUITABILITY

The test is not valid unless, in the chromatogram obtained with solution (3), the resolution between impurity 1 and repaglinide is at least 2.0.

DETERMINATION OF CONTENT

Calculate the content of repaglinide, C\textsubscript{27}H\textsubscript{36}N\textsubscript{2}O\textsubscript{4}, in the tablets from the chromatograms obtained and using the declared content of C\textsubscript{27}H\textsubscript{36}N\textsubscript{2}O\textsubscript{4} in repaglinide BPCRS.

ASSAY

For tablets containing the equivalent of less than 2 mg and/or less than 2% w/w of Repaglinide

Use the average of the individual results determined in the test for Uniformity of content.

For tablets containing the equivalent of 2 mg or more and 2% w/w or more of Repaglinide

Carry out the method for liquid chromatography, Appendix III D, using the following solutions.

(1) To 10 whole tablets, add 75 mL of mobile phase and mix with the aid of ultrasound with occasional shaking. Allow to cool, dilute to 100 mL with mobile phase. Further dilute with mobile phase if necessary to produce a solution containing 0.01% w/v of Repaglinide and filter (a 0.45-µm Millex LCR PTFE filter is suitable).
(2) 0.1% w/v of repaglinide BPCRS in methanol. Dilute 1 volume to 10 volumes with the mobile phase.
(3) 0.001% w/v each of repaglinide BPCRS and repaglinide impurity 1 BPCRS in methanol. Dilute 1 volume to 10 volumes with the mobile phase.

CHROMATOGRAPHIC CONDITIONS

The chromatographic conditions described under Uniformity of content may be used.

SYSTEM SUITABILITY

The test is not valid unless, in the chromatogram obtained with solution (3), the resolution between impurity 1 and repaglinide is at least 2.0.

DETERMINATION OF CONTENT

Calculate the content of repaglinide, C\textsubscript{27}H\textsubscript{36}N\textsubscript{2}O\textsubscript{4}, in the tablets from the chromatograms obtained and using the declared content of C\textsubscript{27}H\textsubscript{36}N\textsubscript{2}O\textsubscript{4} in repaglinide BPCRS.
The impurities limited by the requirements of this monograph include those listed under Repaglinide and:

1. (S)-2-ethoxy-4-[3-methyl-1-[2-(1-piperidinyl)phenyl]-ethyl]amino]-2-oxoethyl]-benzoic acid (USP impurity C)